Hepatocellular carcinoma
Conditions
Interventions
Treatment Group:Immunotherapy combined with targeted therapy
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1: Age between 18 and 75 years, male or female; 2: Radiological and/or pathological diagnosis consistent with the diagnostic criteria for hepatocellular carcinoma (HCC) according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 edition); 3: Patients who have previously received systemic antitumor therapy for HCC (such as anti–PD-1/PD-L1 antibody, T+T, or A+T regimen) and experienced disease progression or intolerance; 4: Child–Pugh score =12 weeks; 8: Signed informed consent and ability to comply with the study protocol and follow-up schedule.
Exclusion criteria
Exclusion criteria: 1: Known hypersensitivity or allergy to study drugs; 2: Known diagnosis of cholangiocarcinoma (ICC), mixed-type hepatocellular carcinoma, hepatoblastoma, or fibrolamellar carcinoma; 3: Known brain metastases; 4: History of other malignancies within the past 5 years that have not been cured or may interfere with study evaluation; 5: Presence of any unresolved >= Grade 2 adverse event (CTCAE) related to prior antitumor therapy; 6: History of immunodeficiency, current use of immunosuppressive agents, or active autoimmune disease; 7: Concurrent severe cardiovascular, heart failure, respiratory disease, or serious acute/chronic infection requiring antiviral treatment (excluding viral hepatitis); 8: Prior treatment with lenvatinib-containing regimens and/or Epaloritovorilil monoclonal antibody plus lenvatinib; 9: Pregnant or breastfeeding women, or women planning pregnancy during the study period; 10: Patients with infectious diseases or other conditions deemed by the investigator to be unable to comply with study treatment and follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Disease Control Rate (DCR);Progression-Free Survival (PFS);Overall Survival (OS);Safety; | — |
Countries
China
Contacts
Public ContactJianbing Wu
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed